Sign in

    Dolph Warburton • Nephron Research

    Dolph Warburton is a Principal at Nephron Research, specializing in Pharma Supply Chain and Digital Health investment research. He provides in-depth analysis of companies across the pharmaceutical supply chain and healthcare IT sectors, leveraging industry experience and a network to deliver actionable insights for institutional investors. Warburton has played a key role at Nephron Research as a lead analyst, though comprehensive performance metrics and historical rankings are not publicly available. His professional background is centered on healthcare research, but details on previous employers, industry credentials, or securities licenses have not been disclosed.

    Dolph Warburton's questions to American Well Corp (AMWL) leadership

    Dolph Warburton's questions to American Well Corp (AMWL) leadership • Q3 2024

    Question

    Dolph Warburton of Nephron Research sought confirmation of the company's target to be cash flow positive by 2026 and asked about the primary risks to achieving this goal.

    Answer

    CFO Mark Hirschhorn confirmed the 2026 cash flow positive target. He identified two main execution risks: achieving the necessary new revenue growth to hit gross margin targets and continuing to successfully manage the company's cost base down to its new stabilized level.

    Ask Fintool Equity Research AI